These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 38255695)

  • 21. Nitazoxanide in the treatment of cryptosporidial diarrhea and other intestinal parasitic infections associated with acquired immunodeficiency syndrome in tropical Africa.
    Doumbo O; Rossignol JF; Pichard E; Traore HA; Dembele TM; Diakite M; Traore F; Diallo DA
    Am J Trop Med Hyg; 1997 Jun; 56(6):637-9. PubMed ID: 9230795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in genetic manipulation of Cryptosporidium.
    Vinayak S
    Curr Opin Microbiol; 2020 Dec; 58():146-152. PubMed ID: 33161368
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis.
    Zhang CX; Love MS; McNamara CW; Chi V; Woods AK; Joseph S; Schaefer DA; Betzer DP; Riggs MW; Iroh Tam PY; Van Voorhis WC; Arnold SLM
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0156021. PubMed ID: 34748385
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic screening techniques for
    Love MS; McNamara CW
    Expert Opin Drug Discov; 2021 Jan; 16(1):59-74. PubMed ID: 32892652
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparative efficacy of curcumin and paromomycin against Cryptosporidium parvum infection in a BALB/c model.
    Asadpour M; Namazi F; Razavi SM; Nazifi S
    Vet Parasitol; 2018 Jan; 250():7-14. PubMed ID: 29329627
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cryptosporidium and cryptosporidiosis.
    Soave R; Armstrong D
    Rev Infect Dis; 1986; 8(6):1012-23. PubMed ID: 3541121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis and control of cryptosporidiosis in farm animals.
    Aboelsoued D; Abdel Megeed KN
    J Parasit Dis; 2022 Dec; 46(4):1133-1146. PubMed ID: 36457776
    [No Abstract]   [Full Text] [Related]  

  • 28. Limitations in the screening of potentially anti-cryptosporidial agents using laboratory rodents with gastric cryptosporidiosis.
    Valigurova A; Peckova R; Dolezal K; Sak B; Kvetonova D; Kvac M; Nurcahyo W; Foitova I
    Folia Parasitol (Praha); 2018 Aug; 65():. PubMed ID: 30152784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug treatment and novel drug target against Cryptosporidium.
    Gargala G
    Parasite; 2008 Sep; 15(3):275-81. PubMed ID: 18814694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-Content Screening for Cryptosporidium Drug Discovery.
    Love MS; McNamara CW
    Methods Mol Biol; 2020; 2052():303-317. PubMed ID: 31452169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A high-throughput phenotypic screen identifies clofazimine as a potential treatment for cryptosporidiosis.
    Love MS; Beasley FC; Jumani RS; Wright TM; Chatterjee AK; Huston CD; Schultz PG; McNamara CW
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005373. PubMed ID: 28158186
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intestinal cryptosporidiosis: pathophysiologic alterations and specific cellular and humoral immune responses in rnu/+ and rnu/rnu (athymic) rats.
    Gardner AL; Roche JK; Weikel CS; Guerrant RL
    Am J Trop Med Hyg; 1991 Jan; 44(1):49-62. PubMed ID: 1996741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Investigation of Cryptosporidium oocysts in elementary school students in Mersin].
    Otağ F; Aslan G; Emekdaş G; Aydin E; Ozkan AT; Ceber K
    Turkiye Parazitol Derg; 2007; 31(1):17-9. PubMed ID: 17471406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the safety, tolerability, pharmacokinetics and efficacy of clofazimine in cryptosporidiosis (CRYPTOFAZ): study protocol for a randomized controlled trial.
    Nachipo P; Hermann D; Quinnan G; Gordon MA; Van Voorhis WC; Iroh Tam PY
    Trials; 2018 Aug; 19(1):456. PubMed ID: 30139372
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevention and treatment of cryptosporidiosis in immunocompromised patients.
    Abubakar I; Aliyu SH; Arumugam C; Hunter PR; Usman NK
    Cochrane Database Syst Rev; 2007 Jan; (1):CD004932. PubMed ID: 17253532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel treatment strategies and drugs in development for cryptosporidiosis.
    Chavez MA; White AC
    Expert Rev Anti Infect Ther; 2018 Aug; 16(8):655-661. PubMed ID: 30003818
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Amelioration of Cryptosporidium parvum infection in vitro and in vivo by targeting parasite fatty acyl-coenzyme A synthetases.
    Guo F; Zhang H; Fritzler JM; Rider SD; Xiang L; McNair NN; Mead JR; Zhu G
    J Infect Dis; 2014 Apr; 209(8):1279-87. PubMed ID: 24273180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New drugs and treatment for cryptosporidiosis.
    Smith HV; Corcoran GD
    Curr Opin Infect Dis; 2004 Dec; 17(6):557-64. PubMed ID: 15640710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current pharmacotherapy of cryptosporidiosis: an update of the state-of-the-art.
    Schneider A; Wendt S; Lübbert C; Trawinski H
    Expert Opin Pharmacother; 2021 Dec; 22(17):2337-2342. PubMed ID: 34281461
    [No Abstract]   [Full Text] [Related]  

  • 40. Characterization of anti-Cryptosporidium IgA antibodies in sera from immunocompetent individuals and HIV-infected patients.
    Kassa M; Comby E; Lemeteil D; Brasseur P; Ballet JJ
    J Protozool; 1991; 38(6):179S-180S. PubMed ID: 1818157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.